Cargando…
Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study
BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis, primarily due to failed early detection. HCC screening is recommended among individuals with cirrhosis using biannual abdominal ultrasound, for earlier tumor detection, administration of curative tre...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995734/ https://www.ncbi.nlm.nih.gov/pubmed/33765926 http://dx.doi.org/10.1186/s12876-021-01714-8 |
_version_ | 1783669971464749056 |
---|---|
author | Lewin, Jörn Kottwitz, Denise Aoyama, Johanna deVos, Theo Garces, Jorge Hasinger, Oliver Kasielke, Stefanie Knaust, Florian Rathi, Preeti Rausch, Sebastian Weiss, Gunter Zipprich, Alexander Mena, Edward Fong, Tse-Ling |
author_facet | Lewin, Jörn Kottwitz, Denise Aoyama, Johanna deVos, Theo Garces, Jorge Hasinger, Oliver Kasielke, Stefanie Knaust, Florian Rathi, Preeti Rausch, Sebastian Weiss, Gunter Zipprich, Alexander Mena, Edward Fong, Tse-Ling |
author_sort | Lewin, Jörn |
collection | PubMed |
description | BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis, primarily due to failed early detection. HCC screening is recommended among individuals with cirrhosis using biannual abdominal ultrasound, for earlier tumor detection, administration of curative treatment, and improved survival. Surveillance by imaging with or without biomarkers such as alpha-fetoprotein (AFP) remains suboptimal for early stage HCC detection. Here we report on the development and assessment of methylation biomarkers from liquid biopsies for HCC surveillance in cirrhotic patients. METHODS: DNA methylation markers including the HCCBloodTest (Epigenomics AG) and a DNA-methylation panel established by next generation sequencing (NGS) were assessed using a training/testing design. The NGS panel algorithm was established in a training study (41 HCC patients; 46 cirrhotic non-HCC controls). For testing, plasma samples were obtained from cirrhotic patients (Child class A or B) with (60) or without (103) early stage HCC (BCLC stage 0, A, B). The assays were then tested using blinded sample sets and analyzed by preset algorithms. RESULTS: The HCCBloodTest and the NGS panel exhibited 76.7% and 57% sensitivities at 64.1% and 97% specificity, respectively. In a post-hoc analysis, a combination of the NGS panel with AFP (20 ng/mL) achieved 68% sensitivity at 97% specificity (AUC = 0.9). CONCLUSIONS: Methylation biomarkers in cell free plasma DNA provide a new alternative for HCC surveillance. Multiomic panels comprising DNA methylation markers with other biological markers, such as AFP, provide an option to further increase the overall clinical performance of surveillance via minimally invasive blood samples. Trial Registration: Test set study—ClinicalTrials.gov (NCT03804593) January 11, 2019, retrospectively registered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-021-01714-8. |
format | Online Article Text |
id | pubmed-7995734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79957342021-03-30 Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study Lewin, Jörn Kottwitz, Denise Aoyama, Johanna deVos, Theo Garces, Jorge Hasinger, Oliver Kasielke, Stefanie Knaust, Florian Rathi, Preeti Rausch, Sebastian Weiss, Gunter Zipprich, Alexander Mena, Edward Fong, Tse-Ling BMC Gastroenterol Research Article BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis, primarily due to failed early detection. HCC screening is recommended among individuals with cirrhosis using biannual abdominal ultrasound, for earlier tumor detection, administration of curative treatment, and improved survival. Surveillance by imaging with or without biomarkers such as alpha-fetoprotein (AFP) remains suboptimal for early stage HCC detection. Here we report on the development and assessment of methylation biomarkers from liquid biopsies for HCC surveillance in cirrhotic patients. METHODS: DNA methylation markers including the HCCBloodTest (Epigenomics AG) and a DNA-methylation panel established by next generation sequencing (NGS) were assessed using a training/testing design. The NGS panel algorithm was established in a training study (41 HCC patients; 46 cirrhotic non-HCC controls). For testing, plasma samples were obtained from cirrhotic patients (Child class A or B) with (60) or without (103) early stage HCC (BCLC stage 0, A, B). The assays were then tested using blinded sample sets and analyzed by preset algorithms. RESULTS: The HCCBloodTest and the NGS panel exhibited 76.7% and 57% sensitivities at 64.1% and 97% specificity, respectively. In a post-hoc analysis, a combination of the NGS panel with AFP (20 ng/mL) achieved 68% sensitivity at 97% specificity (AUC = 0.9). CONCLUSIONS: Methylation biomarkers in cell free plasma DNA provide a new alternative for HCC surveillance. Multiomic panels comprising DNA methylation markers with other biological markers, such as AFP, provide an option to further increase the overall clinical performance of surveillance via minimally invasive blood samples. Trial Registration: Test set study—ClinicalTrials.gov (NCT03804593) January 11, 2019, retrospectively registered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-021-01714-8. BioMed Central 2021-03-25 /pmc/articles/PMC7995734/ /pubmed/33765926 http://dx.doi.org/10.1186/s12876-021-01714-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Lewin, Jörn Kottwitz, Denise Aoyama, Johanna deVos, Theo Garces, Jorge Hasinger, Oliver Kasielke, Stefanie Knaust, Florian Rathi, Preeti Rausch, Sebastian Weiss, Gunter Zipprich, Alexander Mena, Edward Fong, Tse-Ling Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study |
title | Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study |
title_full | Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study |
title_fullStr | Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study |
title_full_unstemmed | Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study |
title_short | Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study |
title_sort | plasma cell free dna methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995734/ https://www.ncbi.nlm.nih.gov/pubmed/33765926 http://dx.doi.org/10.1186/s12876-021-01714-8 |
work_keys_str_mv | AT lewinjorn plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT kottwitzdenise plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT aoyamajohanna plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT devostheo plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT garcesjorge plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT hasingeroliver plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT kasielkestefanie plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT knaustflorian plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT rathipreeti plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT rauschsebastian plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT weissgunter plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT zipprichalexander plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT menaedward plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy AT fongtseling plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy |